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SII: Finnish Social Insurance InstitutionThe Finnish National Asthma Program 1994-2004 markedly
improved asthma care in the 1990s. We evaluated the changes in
costs during 26 years from 1987 to 2013. Direct and indirect
costs were calculated by using data from national registries.
Costs from both the societal and patient perspectives were
included. The costs were based on patients with persistent,
physician-diagnosed asthma verified by lung function
measurements. We constructed minimum and maximum
scenarios to assess the effect of improved asthma care on total
costs. The number of patients with persistent asthma in the
national drug reimbursement register increased from 83,000 to
247,583. Improved asthma control reduced health care use and
disability, resulting in major cost savings. Despite a 3-fold
increase in patients, the total costs decreased by 14%, from
V222 million to V191 million. Costs for medication and primary
care visits increased, but overall annual costs per patient
decreased by 72%, from V2656 to V749. The theoretical total
cost savings for 2013, comparing actual with predicted costs,
were between V120 and V475 million, depending on the
scenario used. The Finnish Asthma Program resulted in
significant cost savings at both the societal and patient
levels during a 26-year period. (J Allergy Clin Immunol
2017;139:408-14.)
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408In most countries the total costs of asthma treatment have
gradually increased because of increased asthma prevalence
and rapidly growing costs of newer drugs.1 In Finland the
prevalence of asthma in adults was approximately 6% in
the 1990s2,3 but has increased since then. In the Helsinki cap-
ital area population-based surveys indicated a prevalence of
physician-diagnosed asthma of 6.8% in 1996 and 9.4% in
2007.4 In adults aged 25 to 64 years, the age-adjusted preva-
lence of physician-diagnosed asthma increased from 6.1% to
9.5% in men and from 7.8% to 10.8% in women from
1997 to 2012.5
In 2013, the Finnish Social Insurance Institution (SII) listed
247,583 patients with physician-diagnosed asthma who were
entitled to special reimbursement for drug costs because of their
need for maintenance medication for persistent disease. This
number was 3 times larger than the equivalent in 1987. The
population of Finland has increased from 4,938,602 to 5,451,270
(10%) during the same period.
Significant advances in asthma care, especially in
diagnostics and pharmacotherapy, have taken place since 1987.
The main changes in pharmacotherapy have been the
use of regular inhaled corticosteroids (ICSs) as first-line
therapy in all asthmatic patients6,7 and the introduction of
new drugs, such as inhaled long-acting b2-agonists (LABAs),
combinations of LABAs and ICSs, and leukotriene receptor
antagonists.
A 10-year national asthma program was established in Finland
from 1994 to 2004 to lessen the burden of disease (Box 1).8 As a
result, overall asthma care improved, patients obtained better
disease control, and costs decreased.9,10 These changes were
achieved through systematic planning, education, and networking
to implement early detection and anti-inflammatory treatment
(mainly ICSs) at all levels of asthma care. The local efforts
improved cooperation between primary and secondary health
care providers.
Encouraged by the good results, a new national allergy
program from 2008 to 2018 was launched to take further
steps to reduce the burden of all allergic conditions, including
asthma.11
We have evaluated whether the systematic approach to improve
asthma management in Finland has resulted in long-term cost
savings. We used Finnish registry data from different sources for
appraisal of the effectiveness of asthma care interventions during
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analysis allowed detection of trends in costs and identification of
relevant cost drivers.DATA AND METHODS
The cost of illness calculations included the direct costs of care (outpatient
visits, hospitalizations, and medication), as well as indirect costs (ie, sickness
allowances and disability pensions). The data on both direct and indirect costs
were based on national registries (see Table E1 in this article’s Online
Repository at www.jacionline.org).12,13 The number of asthmatic patients
was based on the SII registry. This registry includes all patients in Finland
with persistent asthma entitled to special reimbursement for asthma drugs.
The number of patients included in the SII registry is an underestimation of
the true prevalence of asthma because patients are not registered if they
only have intermittent or mild disease not requiring regular medication.
However, the SII registry reliably reflects the number of patients with a
persistent disease and can be used for comparison throughout the observation
period. The diagnostic and reimbursement criteria have been validated and
remained essentially the same.14 The Finnish asthma reimbursement code
(203) identifies patients with significant asthma with great accuracy because
the diagnosis must be verified by objective lung function measurements.15
The patients must also need regular medication, as judged and documented
by their physicians.Health care use and direct costs
All secondary care outpatient visits, emergency care, and hospital
admissions during which asthma was the primary diagnosis in 1987-2013
were collected from national discharge registries maintained by the National
Institute for Health and Welfare. During the observation period, primary care
visits were not registered in Finland and not included in the calculations.
Instead, we estimated primary care visits using the benchmarking database on
asthma care in 10 Finnish cities in 2013 by the Nordic Healthcare Group and
the prevalence of asthma. The national registry also is silent on visits to private
health care providers. Moreover, benefits paid by private insurance companies
were not available. However, private sector services have a negligible role in
inpatient care, whereas they account for about 25%of the number of outpatient
visits (mostly occupational care visits), as estimated by the Nordic Healthcare
Group benchmarking.
The cost estimates were based on average unit costs of an outpatient visit
(general practitioner or specialist) and inpatient hospital days in Finland in
2001.12 All unit costs for other years were estimated by using the health
care cost index available from Statistics Finland.13 Finally, the annual
nominal costs were converted to 2013 prices by using the general price level
index.
The costs of medication were obtained from the annual statistics of the SII,
which records the cost of medication bought by patients eligible for
special reimbursement because of asthma. For patients with intermittent
or mild asthma not included in the SII registry, medication costs were
not available. Annual medication costs were also converted to 2013 price
levels.Indirect costs (lost productivity)
The study included transfer benefits (ie, sick-leave compensations and
disability pensions caused by asthma) as indirect costs and for calculation of
lost productivity.16 Sick-leave data were obtained from the SII statistical
yearbooks for 1989 to 2013; data for 1987 and 1988 were extrapolated with
Constant Average Growth Rate because they were not available in the
yearbooks. This estimate does not include shorter and noncompensated
sickness leaves (<9 days). Data on disability pensions because of asthma
were obtained from the SII statistical yearbooks for 1987-2013 and from the
Finnish Centre for Pensions registries (2003-2013). The cost of lost
productivity was based on the number of sick-leave days and pension days.The average monthly income of the working-age population was obtained
from Statistics Finland.
Intangible elements, such as decreased working capacity at the
workplace, value of lost life years because of premature death, and patients’
quality of life,17 could not be included in the analysis because no data were
available.Cost scenarios
We constructed ‘‘what if’’ scenarios to detect the important cost drivers for
asthma care during the study period. The actual (realized) annual expenditures
of asthma care were compared with the minimum and maximum scenarios of
theoretic annual costs.
In the minimum scenario we assumed that in patients already in the
register in 1987, the numbers of hospital days, sick-leave days, and
disability pensions would decrease from that year onward according to
the general trends in Finland.18 Then we assumed that the 3-fold increase
in prevalence, as reflected by the SII’s registry, would be due to milder
cases of the disease and therefore would not have an increasing effect
on hospitalizations, sick leaves, and disability pensions. Thus in the min-
imum scenario the new patients with ‘‘mild’’ disease would only increase
the medication cost.
In the maximum scenario we assumed that the prevalence of asthma
increased, but the disease severity and care practices remained at the
1987 level. Thus the number of hospital and sick-leave days and
disability pensions would decrease according to the general trend, but
the increasing number of patients would result in an increase in absolute
numbers.
The differences between the observed actual costs and the minimum and
maximum scenarios would indicate the range of the theoretic savings because
of improved care.
In this public register–based study, no ethics approval was
necessary according to Finnish guidelines. The technical appendix, statistical
codes, and data sets are available by request from Fredrik Herse at fredrik.
herse@nhg.fi.RESULTS
Patients
Table I characterizes Finnish persistent asthma prevalence
according to age and sex at the beginning, middle, and end of
the study period. In 1987, there were 83,000 asthmatic patients
(1.6% of the entire population) entitled to special reimbursement
for drug costs. By 2013, the number had increased to 247,583
(4.6%). The increase reflects mainly improved diagnostics
and treatment coverage. The age profile of patients changed
somewhat during the study period. The percentage of working-
age asthmatic patients (16-64 years) decreased from 63% to
55%, whereas the share of those aged 65 years or older increased
from 27% to 38%.18Changes in health care use, disability, and mortality
The number of hospital days in secondary care decreased from
91,650 in 1987 to 12,050 in 2013 (87%), and those in primary care
decreased from 45,300 to 13,300 (71%). In secondary care the
decrease in hospital days per patient per year was 95% (from 1.10
to 0.05 days), and that in primary care was 90% (from 0.54 to
0.05 days). Therewas a shift of outpatient visits from secondary to
primary care because secondary care visits decreased by 38% in
Box 1. Asthma program in Finland 1994-2004: Goals and main themes in 19948
Goals for prevention, treatment, and rehabilitation
1. As many patients as possible with early asthma recover.
2. Asthmatic patients feel well, and their capacity corresponds with age.
3. Percentage of patients with severe and moderate asthma decreases from 40% to 20%.
4. Number of hospital days of asthmatic patients decreases by 50% by the year 2000.
5. Annual costs per patient decrease by 50% as a result of more effective prevention and treatment.
Main themes
d Early diagnosis and anti-inflammatory treatment: ‘‘hit early and hit hard’’
d Guided self-management to stop exacerbations proactively
d Effective networking with general practitioners, nurses, and pharmacists (nomination of asthma-responsible health care
workers)
d Smoking and tobacco smoke decreased by legislation
d Knowledge of asthma increased in key groups
d Scientific research promoted
TABLE I. Demographic data of the asthmatic patients in the
Finnish drug reimbursement register: 1987, 2000, and 2013
1987* 2000 2013
Finnish population (million) 4.9 5.2 5.4
No. of patients 83,000 190,383 247,583
Female sex (%) Not available 53.9 53.2
Prevalence (%) 1.6 3.6 4.4
Age groups (%)
0-15 y 10 14 7
16-64 y 63 56 55
>_65 y 27 30 38
Prevalence in the age group (%)
0-15 y 0.8 2.9 2.0
16-64 y 1.6 3.1 3.8
>_65 y 3.5 7.3 8.9
*Prevalences denote those patients with the need for long-term regular maintenance
medication for asthma control.
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care visits increased by 98% in total. Sick leave days decreased by
70% in total (89% per patient, from 2.44 to 0.24 days). Disability
pensions decreased by 79% in total (93% per patient, from 0.08 to
0.01 pensioners). There were 6,340 patients in 1987 and 1,310
patients in 2013 with disability pensions because of asthma.
There was also a 57% decrease in age-adjusted asthma-related
death rates, from 3.5 to 1.5 per 100,000 per year. In 1987, there
were 163 deaths caused by asthma, of which 11 were patients less
than 45 years of age. In 2013, the total number was 82, and only 1
was less than 45 years of age.
Costs at the societal level
Although therewas a 3-fold increase between 1987 and 2013 in
the number of patients with persistent asthma (prescribed regular
maintenance medication), total annual expenditures on asthma
care decreased by 14% (from V222 million to V191 million)
during the same period (Fig 1). The overall costs in the beginning
and at the end of the study period are shown in Table II divided
into direct and indirect costs.
Direct health care costs associated with asthma increased by
50% from V90 million in 1987 to V135 million in 2013. In the
cost component analysis the costs of hospitalizations decreased
by 73%, from V30 million to V8 million. The costs because of
secondary care outpatient visits remained the same atV24million
per year, but the costs of outpatient drugs increased by 187%,from V33 million to V98 million. The costs because of primary
care outpatient visits increased by 378%, from V1.1 million to
V5.5 million.
Lost productivity measured as sickness allowances and
disability pensions decreased significantly during the same
period by 58%, fromV131 million toV55 million. Sickness ben-
efits represented constantly approximately 10% of these
expenditures.
The most important single cost component at the beginning of
the study period was lost productivity, but this changed to direct
health care costs by 1994.Costs at the patient level
In 2013, 247,583 patients were eligible for special reimburse-
ment of their drug costs and were used for assessment. Between
1987 and 2013, the overall annual costs per patient decreased by
71%, fromV2,670 toV771 (Fig 2 and Table II). Direct health care
costs, including medication expenses, decreased by 55% (from
V1,081 toV545 per patient). Costs of outpatient drugs decreased
by 4%, from V409 to V394 per patient. Lost productivity
dwindled by 86%, from V1,589 to V226 per patient, during the
26-year period.Cost scenarios
Fig 3 shows the actual (realized) annual expenditures for
asthma care in Finland and the minimum andmaximum scenarios
of theoretic development of annual costs. The change in service
use and indirect costs in the scenarios are based on the
general trends in health care in Finland.18 All hospital (inpatient)
days in secondary care (whole population) decreased by 58%,
and those in primary care decreased by 35% from 1987 to
2013. Concomitantly, all secondary care outpatient visits (whole
population) increased by 64%, and disability pensions (working-
age population) decreased by 34%. The decreases for asthmatic
patients were larger than these general trends, resulting in
estimated cost savings of between V120 million (minimum)
and V475 million (maximum) at the end of the observation
period.DISCUSSION
A systematic database search of the English literature from











1987 -89 -91 -93 -95 -97 -99 2001 -03 -05 -07 -09 -11 -13
Lost productivity
Outpatient pharmaceutical costs
Hospitalisation costs in secondary care
Outpatient care costs in secondary care
Hospitalisation costs in primary care
Outpatient care costs in primary care
FIG 1. Overall annual costs of asthma care at the societal level in Finland from 1987 to 2013.
TABLE II. Total costs per patient and for the Finnish asthma
population included in the Finnish drug reimbursement reg-
ister (83,000 patients in 1987 and 247,583 patients in 2013)
1987 2013
Per patient Total Per patient Total
Total direct costs V1,081 V89,698,974 V545 V134,985,376
Hospitalization
Secondary care V295 V24,477,526 V21 V5,209,985
Primary care V69 V5,729,962 V11 V2,720,238
Outpatient care
Secondary care V293 V24,353,930 V97 V24,013,817
Primary care V17 V1,152,583 V22 V5,472,336




V1,589 V131,907,761 V226 V55,838,337
Total direct and
indirect costs
V2,670 V221,606,735 V771 V190,823,713
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Improved asthma care ought to lessen the burden of disease at
both the societal and individual patient level. This has happened
in Finland, where asthma detection and control were improved.
At the start of the Finnish asthma program in 1994, it was
estimated that 20% of the patients had severe (or uncontrolled)
disease.8 This figure decreased to 10% in 2001 and 4% in
2010.22 This led to a significant decrease in health care service
use, sick leaves, and disability pensions. Although medication
costs increased because of increased numbers of patients and
higher costs of new drugs, it did not come anywhere close to
offsetting the major cost savings derived from better disease
control.
During a 26-year period, the total annual societal costs of
asthma diminished by 14%, from V222 million to V191 million,
while the number of patients receiving maintenance medication
registered by the SII tripled. This increase in the number ofpatients reflects mainly better awareness and detection of disease
and coverage of effective treatment. These factorsmight also have
resulted inmilder cases entering the register. However, the criteria
for special reimbursement for drug costs have not changed during
the study period. The cost decrease was remarkable at the patient
level as well.
Cost savings were detected in all relevant paying sectors of
society. In particular, reductions in sickness allowance days and
disability pensions resulted in saved societal costs. An exception
was the increase in outpatient drug costs, with the greatest relative
growth in the latter half of the 1990s. This development was not
surprising because the number of patients receiving an early
diagnosis and effective medication increased.
The clinical efficacy of ICSs was shown already in the early
1970s, but generally, the drug was used with small doses and not
as first-line treatment.23 New pathophysiologic knowledge about
asthma primarily as an inflammatory disease started to evolve
from the mid-1980s.24-26 Early and precise diagnosis, with the
help of effective lung function measurements, was emphasized,
and anti-inflammatory medication with ICSs was introduced as
first-line treatment. The greatest benefit for society was attained
in the 1990s, when this strategy became widespread and before
the launch of fixed combinations of ICSs and LABAs in
1999-2001. Altogether, since 2000, the use of ICSs has increased
only marginally (Fig 3).
One essential key for better patient care was improving
treatment adherence by guided self-management. In 1998, it
was confirmed that educating patients to prevent asthma
exacerbations/attacks proactively was cost-effective compared
with traditional treatment.27 The result was repeated in
subsequent studies, although at first, an intense education process
was costly.28
The cost-effectiveness of the newer therapies cannot be reliably
assessed by a societal cost analysis because the evaluation would
need knowledge on individual or cohort quality of life for
calculation of quality-adjusted life-years. Nevertheless, it is
obvious that earlier and more effective use of the older and
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Use of ICS drugs
FIG 3. Actual (realized) annual expenditures of asthma care (blue columns) and minimum (red columns)
and maximum (gray columns) scenarios of theoretic annual costs. The minimum scenario represents a
theoretic annual expenditure if all of the 3-fold increase in prevalence was caused by patients with mild
asthma. The maximum scenario assumes that the disease severity and standard of care remained at the
1987 level. The green line represents the percentage of patients receiving ICS medication.
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applied in developing countries without jeopardizing their
economies, thereby avoiding the substantial costs of emergency
visits and hospitalizations.
The Finnish Asthma Program 1994-2004, supported by the
Ministry of Health and Social Affairs, translated the new
knowledge rapidly and consistently into clinical practice.8 An
implementation plan was outlined with strategic choices, defined
goals, and measures, as well as activities, such as for capacity
building and funding. Information, education, and effective
networking with different stakeholders were the primary keys.
Patients were taken into the program as active partners, mainly
through nongovernmental patient organizations. Cooperation
between asthma specialists, primary care physicians, nurses,
pharmacists, and the pharmaceutical industry, with the lastmentioned as producers of approved information material,
resulted in rapid implementation of a program that could be
achieved at low costs. A motivating factor was that many of the
studies contributing to the new understanding of asthma
originated from Finnish investigators in the international
context.29,30
Improved asthma care in Finland is an example of how
nationwide implementation of a successful strategy can decrease
overall costs, despite increased numbers of patients needing
treatment. Focused asthma programs have also been effective in
other countries, with associated gains in quality-adjusted
life-years31,32 and improvements in quality of life, asthma
symptoms, and lung function at lower direct costs compared
with usual care.33,34 Several European and other countries have
similar experiences as Finland.35-38 A group of experts, the
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programs in Argentina, Australia, Brazil, China, Japan, Mexico,
Philippines, Russia, South Africa, and Turkey.39 The group
concluded that the major barriers for successful programs are
(1) low rates of dissemination and implementation of treatment
guidelines, (2) low levels of continuing medical education and
training of primary health care professionals, and (3) access and
distribution of ICSs. In the less developed asthma programs, un-
derrecognition and undertreatment further limited the success.
The Finnish financial system for providing care for chronic
diseases, such as asthma, is complicated, as it is in most European
Union countries, and divided into several sectors. The division of
asthma costs in Finland between different stakeholders has
changed considerably, with an increase in drug costs and costs
for outpatient visits in primary care but significant decreases in
hospital costs and indirect costs in terms of disability pensions
and sickness allowances. A holistic view is warranted, and
cooperation is needed among those who provide care and pay
the costs.40 Focusing on risk groups might provide further
improvements.41
Our study has limitations, and the financial results are
probably underestimated. Patients with mild or intermittent
asthma not requiring daily maintenance treatment were
excluded because they are not entitled to drug reimbursement
and not included in the registry. The costs of outpatient
visits to private health care providers are not known. Also,
many of the components of productivity loss could not be
calculated.
In Finland the number of patients receiving reimbursement for
asthma drugs (ie, those receiving maintenance treatment) has
almost tripled over the 26 years covered by this study. During the
same period, the overall health care cost index increased by
37.5% in real terms.13 Despite this, total costs for asthma in
Finland at the end of the period were significantly less than
26 years before. In comparison, over the same period, the costs
of breast cancer have increased by 140% while the number of pa-
tients has doubled.42 From 2000 to 2007, the direct health care
costs for diabetes increased by 60%, and costs for disability
increased by 50%.43
In the United States evaluation methods have been
developed that consider health care costs from the perspective
of payers and society. However, it has been argued that an
analysis of societal costs for a single disease is of little value
and that cost-effectiveness analyses involving both costs and
outcomes would be more feasible.44 Nevertheless, cost of
illness investigations are valuable in the planning, decision
making, and allocation of resources within health care
systems.45 A broad societal approach that demonstrates real
health care expenditures is important when discussing
interventions in public health and medical care.46 The present
article estimates cost of illness changes over a long period of
time, when systematic nationwide intervention has significantly
reduced asthma burden.CONCLUSIONS
Asthma needs public health solutions with implementation of
best clinical practices. In Finland a nationwide management
program based on a better understanding of disease pathophys-
iology resulted in improved care and significant cost savings overa 26-year period. Special focus on particular at-risk groups might
provide further improvements.
The basis of the present report of asthma care costs in Finland is derived
from the governmental, public health care asthma programme 1994-2004
(main results published in Thorax 2001 and 2006). The cost analyses were
further developed in a project concerning several common diseases of public
health concern commissioned by the Pharma Industry Finland (PIF) with the
help of Nordic Healthcare Group (NHG). PIF published a report of the study
findings of the selected chronic diseases, asthma among them. PIF did not
participate in the design of the present, extended asthma study or in the
collection, analysis, and interpretation of data. The final stage of this work was
supported by the European Commission’s 7th Framework Programme under
grant agreement 261357 (MeDALL-project) and a Helsinki University
Hospital grant.
Preliminary asthma data were published in the Finnish Medical Journal in
Finnish (Reissell E, et al. The price of asthma in Finland 1987-2005—costs
and financial benefits of treating a chronic disease. FMJ 2010;65:811-6).
PIF had no part in the decision to submit the article for publication, and no
funding was received. The researchers worked independent of PIF or other
funders during the preparation of the present article.
Key messages
d In many countries there have been major improvements
in asthma care. The Finnish experience indicates that
effective implementation of best practice results in
significant cost savings. Emphasis on early diagnosis and
anti-inflammatory treatment paved the way for improved
care.
d Major societal cost savings can be achieved by reducing
disability caused by asthma.
d Collaboration between all stakeholders is essential to
tackle a public health problem, such as asthma.REFERENCES
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TABLE E1. Finnish data sources registries and estimation methods for the present work
Outcome/cost measure Data source
Data extraction rule
(method) Cost estimation method
Generalizability
(time/area) Comments/data quality






No. of bed days for each
subject
Cost based on total
number of bed
days 3 standard unit
price (national standard
price list)12
Covers all admissions in
the country during
1987-2013
Health care cost index13
was used to estimate
unit costs in other study
years, and general price
index13 was used for
deflating the costs for
other study years in
2013 terms.










No. of bed days for each
subject
Cost based on total no. of
bed days 3 standard
unit price (national
standard price list)12
Covers all admissions in
the country during
1987-2013
Health care cost index13
was used to estimate
unit costs in other study
years, and general price
index13 was used for
deflating the costs for
other study years in
2013 terms.




Outpatient secondary care National discharge
register
Principal diagnosis ICD-
10: J45, J46 (1996-
2013)
No. of visits for each
subject
Cost based on total no. of
visits 3 standard unit
price (national standard
price list)12
Covers all specialist level
ambulatory visits in the
country during 1996-
2013
Visits in years 1987-1995
were extrapolated,
assuming a constant
growth rate based on
average growth rate in
1996-2013
Health care cost index13
was used to estimate
unit costs in other study
years, and general price
index13 was used for
deflating the costs for
other study years in
2013 terms.













No. of visits for each
subject







The number of visits in
the whole country was
estimated by scaling























































Outcome/cost measure Data source
Data extraction rule
(method) Cost estimation method
Generalizability
(time/area) Comments/data quality
the no. of visits in the
sample population to
the whole population.
The no. of other study
years was obtained by
assuming that visits per
patient have remained
constant (visits per
patient 3 no. of
patients). Health care
cost index13 was used
to estimate unit costs in
other study years, and
general price index13
was used for deflating
the costs for other
study years in 2013
terms.














General price index13 was
used for deflating the
costs for other study
years in 2013 terms.
SII registry is reliable










No. of sick-leave days for
each subject
No. of sick-leave days
transformed into lost
work years 3 average
annual income
(national statistics)13
Covers sick leaves longer
than 14 days in the
whole country for
1989-2013
1987 and 1988 are
assumed to be the same
as 1989. General price
index13 was used for
deflating the costs for
other study years in
2013 terms.
SII registry is reliable

















pension) in the whole
country for 1987-2013
General price index13 was
used for deflating the
costs for other study
years in 2013 terms.
SII registry and Finnish
center for pensions
registry are reliable





ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth Revision.
*Inpatient medication included in inpatient care costs.
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